Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes
Launched by NOVO NORDISK A/S · Jan 21, 2012
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2 diabetes mellitus
- • Diet-treated subjects with type 2 diabetes with HbA1c 7.5-9.5 %
- • Subjects with type 2 diabetes in oral anti-diabetic drug (OAD) monotherapy treated with metformin or alpha-glucosidase inhibitors with HbA1c 7.0-9.5%
- • Body mass index (BMI) 18.5-40 kg/m\^2
- • Subjects should have a stable body weight for at least 3 months prior to screening (as judged by the Investigator)
- Exclusion Criteria:
- • Impaired liver function
- • Impaired renal function
- • Clinically significant active cardiovascular disease including history of myocardial infarction within the last 6 months and/or heart failure
- • Any clinically significant abnormal ECG (electrocardiogram)
- • Uncontrolled treated/untreated hypertension
- • Recurrent severe hypoglycaemia as judged by the Investigator
- • Active hepatitis B and/or active hepatitis C
- • Positive human immunodeficiency virus (HIV) antibodies
- • Known or suspected allergy to trial product(s) or related products
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Neuss, , Germany
Patients applied
Trial Officials
Global Clinical Registry (GCR, 1452)
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials